Your browser doesn't support javascript.
Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom.
Recalde, Martina; Roel, Elena; Pistillo, Andrea; Sena, Anthony G; Prats-Uribe, Albert; Ahmed, Waheed-Ul-Rahman; Alghoul, Heba; Alshammari, Thamir M; Alser, Osaid; Areia, Carlos; Burn, Edward; Casajust, Paula; Dawoud, Dalia; DuVall, Scott L; Falconer, Thomas; Fernández-Bertolín, Sergio; Golozar, Asieh; Gong, Mengchun; Lai, Lana Yin Hui; Lane, Jennifer C E; Lynch, Kristine E; Matheny, Michael E; Mehta, Paras P; Morales, Daniel R; Natarjan, Karthik; Nyberg, Fredrik; Posada, Jose D; Reich, Christian G; Rijnbeek, Peter R; Schilling, Lisa M; Shah, Karishma; Shah, Nigam H; Subbian, Vignesh; Zhang, Lin; Zhu, Hong; Ryan, Patrick; Prieto-Alhambra, Daniel; Kostka, Kristin; Duarte-Salles, Talita.
  • Recalde M; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Roel E; Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Pistillo A; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Sena AG; Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Prats-Uribe A; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Ahmed WU; Janssen Research & Development, Titusville, NJ, USA.
  • Alghoul H; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Alshammari TM; Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
  • Alser O; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.
  • Areia C; College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.
  • Burn E; Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.
  • Casajust P; College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.
  • Dawoud D; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • DuVall SL; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Falconer T; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Fernández-Bertolín S; Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.
  • Golozar A; Real-World Evidence, Trial Form Support, Barcelona, Spain.
  • Gong M; Cairo University, Faculty of Pharmacy, Cairo, Egypt.
  • Lai LYH; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
  • Lane JCE; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Lynch KE; Department of Biomedical Informatics, Columbia University, New York, NY, USA.
  • Matheny ME; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Mehta PP; Department of Epidemiology, Johns Hopkins School of Public, Baltimore, MD, USA.
  • Morales DR; Pharmacoepidemiology, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
  • Natarjan K; DHC Technologies co, Ltd, Beijing, China.
  • Nyberg F; Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
  • Posada JD; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.
  • Reich CG; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
  • Rijnbeek PR; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Schilling LM; Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.
  • Shah K; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Shah NH; College of Medicine, The University of Arizona, Tucson, AZ, USA.
  • Subbian V; Division of Population Health and Genomics, University of Dundee, Dundee, UK.
  • Zhang L; Department of Biomedical Informatics, Columbia University, New York, NY, USA.
  • Zhu H; New York-Presbyterian Hospital, New York, NY, USA.
  • Ryan P; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Prieto-Alhambra D; Department of Medicine, Stanford University, Palo Alto, CA, USA.
  • Kostka K; Real World Solutions, IQVIA, Cambridge, MA, USA.
  • Duarte-Salles T; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Int J Obes (Lond) ; 45(11): 2347-2357, 2021 11.
Artículo en Inglés | MEDLINE | ID: covidwho-1315585
ABSTRACT

BACKGROUND:

A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.

METHODS:

We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.

RESULTS:

We included 627 044 (Spain 122 058, UK 2336, and US 502 650) diagnosed and 160 013 (Spain 18 197, US 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.

CONCLUSION:

We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 / Obesidad Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Límite: Adolescente / Adulto / Anciano / Femenino / Humanos / Masculino / Middle aged / Young_adult País/Región como asunto: America del Norte / Europa Idioma: Inglés Revista: Int J Obes (Lond) Asunto de la revista: Metabolismo Año: 2021 Tipo del documento: Artículo País de afiliación: S41366-021-00893-4

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 / Obesidad Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Límite: Adolescente / Adulto / Anciano / Femenino / Humanos / Masculino / Middle aged / Young_adult País/Región como asunto: America del Norte / Europa Idioma: Inglés Revista: Int J Obes (Lond) Asunto de la revista: Metabolismo Año: 2021 Tipo del documento: Artículo País de afiliación: S41366-021-00893-4